Journal for Veterinary Internal Medicine (via Wiley Online Library)

Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs

27-May 2022Background: For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. Insulin fused with immunoglobulin-fragment-crystallizable (Fc) has an ultra-long plasma half-life because it recycles through cells, protected from proteolysis.

Read the paper on Wiley Online Library


ScienceDirect

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

23-February 2022Abstract: To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (SP/RBD) antigen and human IgG1 Fc emulsified in the water-in-oil adjuvant, Montanide™ ISA 720. A single-center, open-label, phase I dose-finding and safety study was conducted with 60 healthy adults (18–65 years) receiving one or two doses 28 days apart of 22.5 µg, 45 µg, or 90 µg of AKS-452 (i.e., six cohorts, N = 10 subjects per cohort).

Read the paper on ScienceDirect.com


AACR Journals

Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer

15 February 2022Abstract: Obesity and metabolic dysfunction are on the rise in the United States. Hyperinsulinemia, frequently seen in these conditions, correlates with an increased risk of development and mortality from estrogen receptor (ER) positive breast cancer. Expression of components of the insulin and insulin-like growth factor (IGF) family of proteins promote cancer cell growth in vitro, link to shorter progression-free survival, and is associates with an increased risk of metastatic disease and death in breast cancer patients.

Read the full abstract on AACRJournals.org


Published in ScienceDirect

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

29 October 2021AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic.

Read the paper on ScienceDirect.com


Published in the Journal of Veterinary Internal Medicine

An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats

30-June 2021Treatment of diabetes mellitus (DM) in cats typically requires insulin injections q12h-q24h, posing a major compliance barrier for caregivers. Novel treatments enabling decreased injection frequency while maintaining safety are highly desirable. Insulin fused with feline immunoglobulin fragment crystallizable (Fc) has an ultra-long plasma half-life because it recycles through cells where it is protected from proteolysis.

Read the paper on the Online Library


Published in the National Center for Biotechnology Information

Disrupting Insulin and IGF Receptor Function in Cancer

8 January 2021The insulin and insulin-like growth factor (IGF) system plays an important role in regulating normal cell proliferation and survival. However, the IGF system is also implicated in many malignancies, including breast cancer. Preclinical studies indicate several IGF blocking approaches, such as monoclonal antibodies and tyrosine kinase inhibitors, have promising therapeutic potential for treating diseases.

Read the paper on the NCBI website


Published in ResearchGate

Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth

February 2020A link between obesity, metabolic dysfunction, and an increased risk in cancer mortality has been well established in several cancer types including, breast, colon, pancreatic, and prostate cancers. A likely mechanism driving this elevated risk is the associated increase in circulating insulin and insulin-like growth factor (IGF), which are known promoters of cancer growth and have been linked to shorter progression-free survival, and increased risk of metastatic disease and death in breast cancer patients. IGF receptor (IGF1R) targeting has been unsuccessful as insulin receptor (IR) also is functional in breast cancers.

Read the paper on ResearchGate.com